Silibinin-mediated metabolic reprogramming attenuates pancreatic cancer-induced cachexia and tumor growth

Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related deaths in the US. Cancer-associated cachexia is present in up to 80% of PDAC patients and is associated with aggressive disease and poor prognosis. In the present studies we evaluated an anti-cancer natural product...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncotarget
Päätekijät: Shukla, Surendra K., Dasgupta, Aneesha, Mehla, Kamiya, Gunda, Venugopal, Vernucci, Enza, Souchek, Joshua, Goode, Gennifer, King, Ryan, Mishra, Anusha, Rai, Ibha, Nagarajan, Sangeetha, Chaika, Nina V., Yu, Fang, Singh, Pankaj K.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Impact Journals LLC 2015
Aiheet:
Research Paper
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4747396/
https://ncbi.nlm.nih.gov/pubmed/26510913
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia